UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 25, 2004
Integrated BioPharma, Inc.
--------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-28876 22-2407475
-------- --------- ----------
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation or organization) Identification No.)
225 Long Avenue
Hillside, New Jersey 07205
-------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (973) 926-0816
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Events and Regulation FD Disclosure.
On June 25, 2004, Integrated BioPharma, Inc., a Delaware corporation
(the "Company"), issued a press release reiterating that the Company had adopted
a stock repurchase program authorizing the Company to repurchase shares of the
Company's common stock worth up to $3 million, and that the Company was not, at
the time of such press release, aware of any reason for the recent unusual
trading activity affecting its common stock. The press release is attached as an
exhibit to this Report.
Item 7. Financial Statements and Exhibits
(c) Exhibits.
Exhibit No. Description
99.1 Press Release issued by Integrated BioPharma, Inc. on June 25, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: June 29, 2004 INTEGRATED BIOPHARMA, INC.
By: /s/ Eric Friedman
Eric Friedman
Vice President and Chief Financial Officer
Exhibit Index
Exhibit No. Description
99.1 Press Release issued by Integrated BioPharma, Inc. on June 25, 2004